Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Andecaliximab |
| Trade Name | |
| Synonyms | GS-5745 |
| Drug Descriptions |
Andecaliximab (GS-5745) is a monoclonal antibody that binds to and inhibits matrix metalloproteinase 9 (MMP-9), which may lead to inhibition of matrix degradation and tumor metastasis (PMID: 25961845, PMID: 29691300). |
| DrugClasses | |
| CAS Registry Number | 1518996-49-0 |
| NCIT ID | C105803 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Andecaliximab | Andecaliximab | 0 | 2 |
| Andecaliximab + Bevacizumab | Andecaliximab Bevacizumab | 0 | 1 |
| Andecaliximab + Fluorouracil + Leucovorin + Oxaliplatin | Andecaliximab Fluorouracil Leucovorin Oxaliplatin | 0 | 0 |
| Andecaliximab + Nivolumab | Andecaliximab Nivolumab | 0 | 1 |